What were Ipca Laboratories Ltd's latest quarterly results?
Ipca Laboratories Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +379.7%
- Revenue Growth YoY: +6.3%
- Operating Margin: 20.0%
Ipca Laboratories Ltd: Stock Analysis & Fundamentals
Updated this weekIpca Laboratories Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 34.2. ROE: 16.0%. This stock is not currently in the Nifty 500 momentum outperformers list.
Ipca Laboratories Ltd Key Facts
What's Happening
📊Debt increased 58% YoY — leverage rising
👔Promoter stake down 1.6% this quarter
🏛️DII accumulation — stake up 2.6%
Key Numbers
Current Price
₹1,621
Dividend Yield
0.25%
Market Cap
41.1K Cr
Valuation
N/AOther Top Pharma - Formulators Stocks Beating Nifty 500
Frequently Asked Questions: Ipca Laboratories Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What is Ipca Laboratories Ltd's current PE ratio?
Ipca Laboratories Ltd's current PE ratio is 34.2x.
- Current PE: 34.2x
- Market Cap: 41.1K Cr
- Dividend Yield: 0.25%
What is Ipca Laboratories Ltd's price-to-book ratio?
Ipca Laboratories Ltd's price-to-book ratio is 5.1x.
- Price-to-Book (P/B): 5.1x
- Book Value per Share: ₹318
- Current Price: ₹1621
Is Ipca Laboratories Ltd a fundamentally strong company?
Ipca Laboratories Ltd's fundamental strength based on key financial ratios
- Return on Capital (ROCE): 17.0%
Is Ipca Laboratories Ltd debt free?
Ipca Laboratories Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹809 Cr
What is Ipca Laboratories Ltd's return on equity (ROE) and ROCE?
Ipca Laboratories Ltd's return ratios over recent years
- FY2024: ROCE 13.0%
- FY2025: ROCE 15.0%
- FY2026: ROCE 17.0%
Is Ipca Laboratories Ltd's cash flow positive?
Ipca Laboratories Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹1,000 Cr
- Free Cash Flow (FCF): ₹895 Cr
- CFO/PAT Ratio: 96% (strong cash conversion)
What is Ipca Laboratories Ltd's dividend yield?
Ipca Laboratories Ltd's current dividend yield is 0.25%.
- Dividend Yield: 0.25%
- Current Price: ₹1621
Who holds Ipca Laboratories Ltd shares — promoters, FII, DII?
Ipca Laboratories Ltd's shareholding pattern (Mar 2026)
- Promoters: 44.7%
- FII (Foreign): 10.6%
- DII (Domestic): 37.1%
- Public: 7.2%
Is promoter holding increasing or decreasing in Ipca Laboratories Ltd?
Ipca Laboratories Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 44.7% (Mar 2026)
- Previous Quarter: 44.7% (Dec 2025)
- Change: 0.00% (stable)
Is Ipca Laboratories Ltd a new momentum entry or an established outperformer?
Ipca Laboratories Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Is Ipca Laboratories Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Ipca Laboratories Ltd may be worth studying
- Cash flow is positive — CFO ₹1,000 Cr
What is the investment thesis for Ipca Laboratories Ltd?
Ipca Laboratories Ltd investment thesis summary:
What is the future outlook for Ipca Laboratories Ltd?
Ipca Laboratories Ltd's forward outlook based on current data signals
- Insufficient data for a forward assessment — monitoring for more signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.